Ronald Dorenbos, Ph.D., Takeda Pharmaceuticals

Ronald Dorenbos, Ph.D. Ronald is Associate Director at Takeda’s Materials & Innovation group and part of Takeda’s Digital Strategy team for neuroscience. During his appointment at the Life Science division of PA Consulting Group, a British Consulting firm, Ronald led projects for some of the world’s top 10 pharmaceutical companies that included projects around strategy, commercialization and digital health. At his company BioFrontline he provides management, strategy and commercial advice to life science companies around the world. Ronald received MAs in Biotechnology and Molecular Biology and after obtaining a PhD in Pharmaceutical Biology spent six years at Harvard to study Parkinson’s, Schizophrenia and the genetics of aggressive behavior before making the transition to industry. Ronald is a keen follower of applications of AI and deep learning in pharma and healthcare and is the founder of ‘AI – Artificial Intelligence’, a group on LinkedIn that follows the latest developments in AI.


3:15 PM - 3:50 PM

Patient Selection, Recruitment & Retention

  • Patient selection using AI to filter and improve results and share a roadmap explaining how the technology is being used.
  • How AI is changing the clinical trial enrollment process by transforming the way researchers identify and recruit eligible patients.
  • Using AI and NLP to mine structured and unstructured patient data leads to finding better-matching patients for trials in minutes not months.
  • How AI is improving the process of conducting clinical trials, specifically the impact on patient retention through AI applications in monitoring and diagnostic.
  • Findings on how patients view the use of AI in their trials.



Download Latest Agenda